Who AI recommends, and when it changes.
Data as of Mar 30, 2026 · Based on 15 AI answers · A buyer need in Biopharma Research Platforms and Services. · See how Parse measures this
Recommendation share
Olink leads at 40% of AI recommendations; Alamar Biosciences follows at 13%.
By platform
Both platforms lead with Olink.
Representative prompts behind this market ranking, and how AI tends to answer.
Between late March 2026 and late March 2026, 
Why here: The most frequently cited platform, appearing in both standalone recommendations and comparative references for correlation studies and multiplex panels. · 6 sources
Why here: Listed as a key option for protein biomarker immunoassays in overview answers alongside NULISA and Olink. · 2 sources
“Which platform maps biomarkers to assays with practical comparisons?”
AI assistants responded by comparing multiplex immunoassay platforms and informatics tools. They frequently highlighted
